Consolidated cash flow statements
(unaudited)
|
Six months ended 30 June |
|
|---|---|---|
(thousands of €) |
2023 |
2022 |
Net profit/loss (-) of the period |
28,308 |
(32,338) |
|
|
|
Adjustment for non-cash transactions |
47,603 |
6,567 |
Adjustment for items to disclose separately under operating |
(13,155) |
3,529 |
Adjustment for items to disclose under investing and financing |
(7,123) |
(416) |
Change in working capital other than deferred income |
(18,545) |
46,034 |
Cash used for other liabilities related to the acquisition of subsidiaries |
- |
(7,765) |
Decrease in deferred income |
(264,931) |
(209,428) |
Cash used in operations |
(227,843) |
(193,818) |
|
|
|
Interest paid |
(3,472) |
(7,417) |
Interest received |
12,125 |
757 |
Corporate taxes paid |
(1,096) |
(3,262) |
Net cash flow used in operating activities |
(220,286) |
(203,740) |
Purchase of property, plant and equipment |
(8,065) |
(15,574) |
Purchase of and expenditure in intangible fixed assets |
(28) |
(1,783) |
Proceeds from disposal of property, plant and equipment |
2,212 |
- |
Purchase of current financial investments |
(2,212,112) |
(1,842,495) |
Interest received related to current financial investments |
5,356 |
210 |
Sale of current financial investments |
2,024,877 |
903,763 |
Cash out from acquisition of subsidiaries, net of cash acquired |
- |
(115,178) |
Cash advances and loans to third parties |
- |
(10,000) |
Net cash flow used in investing activities |
(187,760) |
(1,081,057) |
|
|
|
Payment of lease liabilities |
(3,511) |
(3,980) |
Proceeds from capital and share premium increases from exercise of subscription rights |
1,770 |
3,619 |
Net cash flow used in financing activities |
(1,741) |
(361) |
|
|
|
Decrease in cash and cash equivalents |
(409,787) |
(1,285,158) |
|
|
|
Cash and cash equivalents at beginning of the period |
508,117 |
2,233,368 |
|
|
|
Decrease in cash and cash equivalents |
(409,787) |
(1,285,158) |
|
|
|
Effect of exchange rate differences on cash and cash equivalents |
(306) |
24,586 |
|
|
|
Cash and cash equivalents at end of the period |
98,024 |
972,796 |
The accompanying notes form an integral part of these condensed consolidated financial statements.